Title 21, Food and DrugsRelease 119-110

§356j Discontinuance or Interruption in the Production of Medical Devices

Title 21 › CHAPTER 9 — FEDERAL FOOD, DRUG, AND COSMETIC ACT › SUBCHAPTER V — DRUGS AND DEVICES › Part A — Drugs and Devices › § 356j

Last updated Sep 23, 2026|Official source

Summary

Manufacturers of medical devices that are critical in a public health emergency—like life-support, life-sustaining, or devices used in emergency care or surgery—or any device the Secretary says needs monitoring, must tell the Secretary if they plan to stop making the device permanently (unless it’s because of an approved change) or if they expect a manufacturing interruption that is likely to cause a meaningful drop in supply in the United States. They must give this notice at least 6 months before the stoppage or interruption, or as soon as they can if 6 months is not possible. The Secretary will share reported information with doctors, hospitals, patient groups, and supply partners when appropriate, but can withhold details if sharing would harm public health (for example, by causing hoarding). Trade secrets and legally protected confidential information cannot be disclosed. If a manufacturer fails to notify, the Secretary will send a letter. The manufacturer then has 30 calendar days to explain and provide the required information. The Secretary will post the letter and response online within 45 calendar days, with confidential parts redacted, unless the Secretary finds the notice was issued in error or the manufacturer had a reasonable excuse. If a shortage is likely, the Secretary may fast-track reviews or inspections for devices or manufacturers that could help fix the shortage. The Secretary must keep a current public list of devices in shortage. Each listing will show the device name or category, makers, the reason for the shortage (one of eight types, such as manufacturing practice problems, regulatory delays, part shortages, discontinuance, shipping or sterilization delays, demand increases, or facility closure), and the Secretary’s estimate of how long the shortage will last. The Secretary can accept voluntary notices from manufacturers about planned stoppages or interruptions for critical devices. This summary does not change the Secretary’s authority, as of March 27, 2020, to speed device reviews or use emergency authorization powers. Definitions: “meaningful disruption” = a production change likely to cause more than a small reduction in supply and affect the maker’s ability to fill orders (does not include brief routine maintenance or short pauses expected to end within 6 months, certain component interruptions that do not cause a device shortage, or interruptions that don’t reduce procedures for multi-use devices); “shortage” = when demand or projected demand in the U.S. is greater than supply.

Full Legal Text

Title 21, §356j

Food and Drugs, Source: USLM XML via OLRC

(a)In general
A manufacturer of a device that—
(1)is critical to public health during a public health emergency, including devices that are life-supporting, life-sustaining, or intended for use in emergency medical care or during surgery; or
(2)for which the Secretary determines that information on potential meaningful supply disruptions of such device is needed during, or in advance of, a public health emergency;
shall, during, or in advance of, a public health emergency declared by the Secretary under section 247d of title 42, notify the Secretary, in accordance with subsection (b), of a permanent discontinuance in the manufacture of the device (except for discontinuances as a result of an approved modification of the device) or an interruption of the manufacture of the device that is likely to lead to a meaningful disruption in the supply of that device in the United States, and the reasons for such discontinuance or interruption.
(b)Timing
A notice required under subsection (a) shall be submitted to the Secretary—
(1)at least 6 months prior to the date of the discontinuance or interruption; or
(2)if compliance with paragraph (1) is not possible, as soon as practicable.
(c)Distribution
(1)Public availability
To the maximum extent practicable, subject to paragraph (2), the Secretary shall distribute, through such means as the Secretary determines appropriate, information on the discontinuance or interruption of the manufacture of devices reported under subsection (a) to appropriate organizations, including physician, health provider, patient organizations, and supply chain partners, as appropriate and applicable, as described in subsection (g).
(2)Public health exception
The Secretary may choose not to make information collected under this section publicly available pursuant to this section if the Secretary determines that disclosure of such information would adversely affect the public health, such as by increasing the possibility of unnecessary over purchase of product, component parts, or other disruption of the availability of medical products to patients.
(d)Confidentiality
Nothing in this section shall be construed as authorizing the Secretary to disclose any information that is a trade secret or confidential information subject to section 552(b)(4) of title 5 or section 1905 of title 18.
(e)Failure to meet requirements
If a person fails to submit information required under subsection (a) in accordance with subsection (b)—
(1)the Secretary shall issue a letter to such person informing such person of such failure;
(2)not later than 30 calendar days after the issuance of a letter under paragraph (1), the person who receives such letter shall submit to the Secretary a written response to such letter setting forth the basis for noncompliance and providing information required under subsection (a); and
(3)not later than 45 calendar days after the issuance of a letter under paragraph (1), the Secretary shall make such letter and any response to such letter under paragraph (2) available to the public on the internet website of the Food and Drug Administration, with appropriate redactions made to protect information described in subsection (d), except that, if the Secretary determines that the letter under paragraph (1) was issued in error or, after review of such response, the person had a reasonable basis for not notifying as required under subsection (a), the requirements of this paragraph shall not apply.
(f)Expedited inspections and reviews
If, based on notifications described in subsection (a) or (h) or any other relevant information, the Secretary concludes that there is, or is likely to be, a shortage of an device, the Secretary shall, as appropriate—
(1)prioritize and expedite the review of a submission under section 360c(f)(2) of this title, 360e of this title, review of a notification under section 360(k) of this title, or 360j(m) of this title for a device that could help mitigate or prevent such shortage; or
(2)prioritize and expedite an inspection or reinspection of an establishment that could help mitigate or prevent such shortage.
(g)Device shortage list
(1)Establishment
The Secretary shall establish and maintain an up-to-date list of devices that are determined by the Secretary to be in shortage in the United States.
(2)Contents
For each device included on the list under paragraph (1), the Secretary shall include the following information:
(A)The category or name of the device in shortage.
(B)The name of each manufacturer of such device.
(C)The reason for the shortage, as determined by the Secretary, selecting from the following categories:
(i)Requirements related to complying with good manufacturing practices.
(ii)Regulatory delay.
(iii)Shortage or discontinuance of a component or part.
(iv)Discontinuance of the manufacture of the device.
(v)Delay in shipping of the device.
(vi)Delay in sterilization of the device.
(vii)Demand increase for the device.
(viii)Facility closure.
(D)The estimated duration of the shortage as determined by the Secretary.
(3)Public availability
(A)In general
Subject to subparagraphs (B) and (C), the Secretary shall make the information in the list under paragraph (1) publicly available.
(B)Trade secrets and confidential information
Nothing in this subsection shall be construed to alter or amend section 1905 of title 18 or section 552(b)(4) of title 5.
(C)Public health exception
The Secretary may elect not to make information collected under this subsection publicly available if the Secretary determines that disclosure of such information would adversely affect the public health (such as by increasing the possibility of hoarding or other disruption of the availability of the device to patients).
(h)Additional notifications
The Secretary may receive voluntary notifications from a manufacturer of a device that is life-supporting, life-sustaining, or intended for use in emergency medical care or during surgery, or any other device the Secretary determines to be critical to the public health, pertaining to a permanent discontinuance in the manufacture of the device (except for any discontinuance as a result of an approved modification of the device) or an interruption of the manufacture of the device that is likely to lead to a meaningful disruption in the supply of that device in the United States, and the reasons for such discontinuance or interruption.
(i)Rule of construction
Nothing in this section shall be construed to affect the authority of the Secretary on March 27, 2020, to expedite the review of devices under section 360e of this title, section 360e–3 of this title relating to the priority review program for devices, and section 360bbb–3 of this title relating to the emergency use authorization authorities.
(j)Definitions
In this section: (1) Meaningful disruption
(2)Shortage
The term “shortage”, with respect to a device, means a period of time when the demand or projected demand for the device within the United States exceeds the supply of the device.

Legislative History

Notes & Related Subsidiaries

Editorial Notes

Amendments

2022—Subsec. (f). Pub. L. 117–328, § 2514(a)(1), inserted “or (h)” after “subsection (a)” in introductory provisions. Subsecs. (h) to (j). Pub. L. 117–328, § 2514(a)(2), (3), added subsec. (h) and redesignated former subsecs. (h) and (i) as (i) and (j), respectively.

Statutory Notes and Related Subsidiaries

Guidance on Voluntary Notifications of Discontinuance or Interruption of Device Manufacture Pub. L. 117–328, div. FF, title II, § 2514(b), Dec. 29, 2022, 136 Stat. 5806, provided that: “Not later than 1 year after the date of enactment of this Act [Dec. 29, 2022], the Secretary shall issue draft guidance to facilitate voluntary notifications under subsection (h) of section 506J of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356j), as added by subsection (a). Such guidance shall include a description of circumstances in which a voluntary notification under such subsection (h) may be appropriate, recommended timeframes for such a notification, the process for receiving such a notification, and actions the Secretary may take to mitigate or prevent a shortage resulting from a discontinuance or interruption in the manufacture of a device for which such notification is received. The Secretary shall issue final guidance not later than 1 year after the close of the comment period for the draft guidance.” Guidance on Device Shortage Notification Requirement Pub. L. 117–328, div. FF, title II, § 2514(c), Dec. 29, 2022, 136 Stat. 5806, provided that: “Not later than 1 year after the date of enactment of this Act [Dec. 29, 2022], the Secretary shall issue or revise draft guidance regarding requirements under section 506J of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356j). Such guidance shall include a list of each device product code for which a manufacturer of such device is required to notify the Secretary in accordance with section 506J.”

Reference

Citations & Metadata

Citation

21 U.S.C. § 356j

Title 21, Food and Drugs

Last Updated

Sep 23, 2026

Release point: 119-110